NCT01316718

Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)

Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D).

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 108 (actual)
• Sponsor: University of Nottingham · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the trial is to define the clinical benefit and possible mediators of the benefit of mesalazine in Irritable Bowel Syndrome (IBS) with diarrhoea. The investigators will therefore evaluate symptoms (primarily bowel frequency) and markers reflecting mast cell activation and small bowel tone.

Conditions

• Irritable Bowel Syndrome With Diarrhoea

Interventions

Type	Name	Description
DRUG	Mesalazine	2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
DRUG	Placebo	2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks

Timeline

• Start date: 2011-03-01
• Primary completion: 2013-09-01
• Completion: 2013-09-01
• First posted: 2011-03-16
• Last updated: 2014-01-17

Locations

1 site across 1 country: United Kingdom